|Print Page Close Window|
BeiGene, Ltd. (“BeiGene”) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.
BeiGene has a broad portfolio consisting of six internally-developed, clinical-stage, drug candidates, including three late-stage clinical drug candidates, zanubrutinib (BTK inhibitor), tislelizumab (PD-1 antibody), and pamiparib (PARP inhibitor). BeiGene has also in-licensed six drugs and drug candidates, including three marketed drugs in China ABRAXANE®, REVLIMID® and VIDAZA® under an exclusive license from Celgene Corporation, and three clinical-stage drug candidates with development and commercialization rights in China and other selected countries in the Asia-Pacific region.
Founded in Beijing in 2010, BeiGene was listed on the U.S. NASDAQ Global Select Market in February 2016 and on the Stock Exchange of Hong Kong Limited (HKEx) in August 2018. As of February 2019, the Company had a global team of over 2,200 employees. BeiGene operates as a fully-integrated global biotechnology company with broad capabilities, both in China and globally, spanning research, clinical development, manufacturing and commercialization.
© 2016 BeiGene. All Rights Reserved.